T2 Biosystems, INC 8-K filings

T2 Biosystems reports a significant overhaul of its leadership team, including the resignation of multiple directors and officers, and the appointment of Craig R. Jalbert as the new CEO, President, Corporate Treasurer, and Corporate Secretary.

T2 Biosystems, following a significant workforce reduction, is actively seeking a sale of its assets, including patents and intellectual property, with the assistance of an advisory firm.

T2 Biosystems faces delisting from Nasdaq, implements a significant workforce reduction, and restructures executive roles through consulting agreements.

T2 Biosystems faces delisting from the Nasdaq Stock Market due to non-compliance with listing rules and will transition to the OTC Markets system.

T2 Biosystems has modified its term loan agreement, extending key payment deadlines and altering interest terms to improve its financial position.

T2 Biosystems announced record product revenues for both the fourth quarter and full year 2024, driven by strong sepsis test sales and strategic partnerships.

T2 Biosystems held its annual meeting where stockholders approved an amended incentive plan, elected directors, and ratified the appointment of auditors.

T2 Biosystems has received a delisting notice from Nasdaq due to its stock price falling below $1.00 and its market capitalization dropping below $35 million, and is requesting a hearing to appeal the decision.

T2 Biosystems plans to license its direct-from-whole-blood sepsis detection technology to other diagnostic firms, aiming to generate non-dilutive capital and expand market reach.

T2 Biosystems announced a 34% increase in total revenue for the third quarter of 2024, driven by strong growth in sepsis test panel sales and international instrument placements, alongside strategic partnerships and pipeline advancements.

T2 Biosystems received a delisting notice from Nasdaq due to its market value falling below the required minimum, and the company plans to appeal the decision.

T2 Biosystems reports significant progress with a new exclusive U.S. distribution agreement with Cardinal Health, a collaboration with Prxcision for AI-powered antibiotic stewardship, and FDA clearance for pediatric use of its T2Candida Panel.

T2 Biosystems announced a 35% year-over-year increase in total revenue for the third quarter of 2024, driven by strong sales of sepsis testing products and instrument placements.

T2 Biosystems has successfully defended its key patent for direct-from-whole blood pathogen detection in the European Union against an opposition filed by bioMerieux and others.

T2 Biosystems has received FDA clearance to market its T2Candida Panel for pediatric patients, expanding its market reach to over 200 children's hospitals in the U.S.

T2 Biosystems is progressing its product pipeline, aiming to launch multiple direct-from-blood diagnostic tests for antimicrobial resistance, pediatric infections, Lyme disease, and Candida auris.

T2 Biosystems achieved record sepsis test revenue in the second quarter of 2024, driven by increased sales of its T2Bacteria and T2Resistance panels, while also advancing its product pipeline and strengthening its financial position.

T2 Biosystems has terminated its Equity Distribution Agreement with Canaccord Genuity, effective July 19, 2024, without incurring any penalties.

T2 Biosystems has regained compliance with Nasdaq's market value of listed securities requirement, avoiding delisting.

T2 Biosystems has finalized a private placement, raising approximately $8 million through the sale of common stock and warrants to an institutional investor.

T2 Biosystems amended its Series A and B preferred stock terms, leading to CRG converting its holdings and becoming a 69% majority shareholder.

T2 Biosystems is considering amending its preferred stock agreements to remove ownership blockers, potentially leading to a significant increase in CRG's stake to approximately 69% of the company's outstanding shares.

T2 Biosystems reports a 25% increase in sepsis product revenue and a significant reduction in debt through a debt-for-equity swap.

T2 Biosystems has finalized a $15 million debt-for-equity exchange and amended its term loan agreement, extending the period for in-kind interest payments.

T2 Biosystems' stockholders approved the conversion of CRG debt to equity at a special meeting held on April 11, 2024.

T2 Biosystems has extended its multi-year capital equipment supplier agreement with Vizient, Inc. through March 31, 2025, ensuring continued access to its sepsis detection technology for Vizient's extensive network of healthcare providers.

T2 Biosystems plans to launch the T2Lyme Panel as a laboratory developed test in Q3 2024, alongside other business updates including progress on T2Biothreat and T2Resistance panels.

T2 Biosystems reports a new study demonstrating the T2Resistance Panel's high accuracy and rapid turnaround time in detecting antibiotic resistance genes, leading to improved clinical interventions.

T2 Biosystems has been granted continued listing on the Nasdaq, contingent on demonstrating a market value of at least $35 million by May 20, 2024.

T2 Biosystems reported its 2023 financial results, detailed its plan to regain Nasdaq compliance, and outlined its objectives for 2024, including new product launches and sales growth.